Observational study of the use of 7% sodium chloride solution combined with 0,1% hyaluronic acid in therapy of adults with cystic fibrosis

• Main Authors: S. A. Krasovsky, E. L. Amelina, A. V. Chernyak, E. I. Kondratieva, J. V. Gorinova, O. G. Zonenko, D. F. Sergienko, A. R. Tatarsky
• Format: Article
• Language: Russian
• Published: Remedium Group LLC 2019-01-01
• Series: Медицинский совет
• Subjects: cystic fibrosis; hypertonic solution; hyaluronic acid; mucolytic therapy
• Online Access: https://www.med-sovet.pro/jour/article/view/2819

A non-interventional prospective cohort study was conducted on adult patients with cystic fibrosis, who received mucolytic therapy with 7% NaCl solution combined with 0.1% hyaluronic acid (medical product Hyaneb) and 7% NaCl solution for 4 and 8 weeks. Materials and methods: A total of 24 CF patients over 18 years old were enrolled in the study. A comparative analysis of respiratory function, therapy satisfaction, efficacy and safety of treatment was conducted following 4 weeks of therapy in 7% NaCl Solution Group (n = 12) and MP Hyaneb Group (n = 12), and the dynamics of these parameters was assessed against the background of the use of MP Hyaneb for 8 weeks (n = 12). Results: At week 4 of treatment, a significantly smaller number of patients complained of nasal congestion, ears and or accumulation of mucus in the throat and chest, irritation of the throat and unpleasant taste in the MP Hyaneb Group. No significant differences in the onset and increase in the intensity of cough were achieved. No significant differences between the groups in terms of spirometry parameters were identified. Findings: MP Hyaneb showed the best tolerability compared to 7% NaCl solution in adult patients with cystic fibrosis. The use of MP Hyaneb reduces the frequency and severity of irritation of the pharyngeal mucosa, cough and nasal congestion following administration for one month.